Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology

Igor Pantic, Jelena Cumic, Sanja Radojevic Skodric, Stefan Dugalic, Claude Brodski

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Oxidopamine (6-hydroxydopamine, 6-OHDA) is a toxin commonly used for the creation of experimental animal models of Parkinson's disease, attention-deficit hyperactivity disorder, and Lesch–Nyhan syndrome. Its exact mechanism of action is not completely understood, although there are many indications that it is related to the generation of reactive oxygen species (ROS), primarily in dopaminergic neurons. In certain experimental conditions, oxidopamine may also cause programmed cell death via various signaling pathways. Oxidopamine may also have a significant impact on chromatin structure and nuclear structural organization in some cells. Today, many researchers use oxidopamine–associated oxidative damage to evaluate different antioxidant-based pharmacologically active compounds as drug candidates for various neurological and non-neurological diseases. Additional research is needed to clarify the exact biochemical pathways associated with oxidopamine toxicity, related ROS generation and apoptosis. In this short review, we focus on the recent research in experimental physiology and pharmacology, related to the cellular and animal experimental models of oxidopamine - mediated toxicity.

Original languageEnglish
Article number109380
JournalChemico-Biological Interactions
StatePublished - 25 Feb 2021


  • 6-hydroxydopamine
  • Apoptosis
  • Reactive oxygen species
  • Toxicology

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology'. Together they form a unique fingerprint.

Cite this